Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paige A. Taylor has a total of 96 co-authors. Here are the top co-authors by number of shared publications:

  • Stephen Frasier Kry

    Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    6 shared publications
  • David S. Followill

    IROC Houston Quality Assurance Center, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas

    3 shared publications
  • Nadia Hernandez

    Department of Radiation Physics. The University of Texas MD Anderson Cancer Center, Houston, USA

    3 shared publications
  • Paola Alvarez

    Department of Radiation Physics. The University of Texas MD Anderson Cancer Center, Houston, USA

    3 shared publications
  • Shannon Hartzell

    Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224, USA

    3 shared publications
  • Stephen F. Kry

    Department of Radiation Physics The University of MD Anderson Cancer Center Houston Texas USA

    3 shared publications

Latest Publications

  • Dose delivery accuracy of advanced radiotherapy: 30 years of end-to-end dosimetry audits

    by Stephen F. Kry, Andrea Molineu, Paola Alvarez, Mallory Glenn, Jessica Lowenstein, Nadia Hernandez, Trang Nguyen, Paige Taylor


  • Current Practice for Electronic Medical Device Management in Radiation Therapy

    by A. Gearhardt, J. Pollard-Larkin, C. Peeler, P. Taylor, S. Shete, C. Best, S. Kry

  • Open Access

    Calculating the relative biological effectiveness of carbon ion radiotherapy by common models using measurable microdosimetric inputs

    by Shannon Hartzell, Fada Guan, Paige Taylor, Alfredo Mirandola, Giuseppe Magro, Mario Ciocca, Stephen Kry

  • Open Access

    Trends and Challenges: A 15-Year Review of Imaging and Radiation Oncology Core Anthropomorphic Phantom Audits for Proton Therapy

    by Lian Duan, Hunter S. Mehrens, Stephen F. Kry, Jessica R.L. Lowenstein, Nadia Hernandez, Lucas B. Acuna Scafati, Paige A. Taylor


  • Open Access

    Reference dosimetry data and machine performance comparison for tomotherapy delivery systems audited by IROC

    by Paige A. Taylor, Hunter Mehrens, Mallory C. Glenn, Fre'ETta Brooks, Hayden Scott, Lian Duan, Taylor Meyers, Diana Carrasco Rojas, Michael Yang, Paola Alvarez, et al.

    The aim of this work was to compare the imaging and radiation oncology core (IROC) on‐site TomoTherapy dosimetry measurement results among institutions and generate a dataset of basic dosimetric properties for TomoTherapy units. Independent ion chamber measurements for nine TomoTherapy units were acquired by IROC physicists between 2008 and 2023. Measurements included percent depth dose (PDD) in a water tank and off axis factors (OAF) in a solid Polystyrene phantom. The independent measurements collected during the on‐site audits for each TomoTherapy system were compared to corresponding TomoTherapy TPS calculations from the institution to assess agreement. Numeric measurement values and comparative ratios are compiled and tabulated according to measurement type (i.e., PDD and OAF). The distribution of the measurements was evaluated, and the mean, standard deviation of the mean, and median values are reported. These data provide an independent guide describing the inherent performance characteristics of TomoTherapy units. Such data may serve as a secondary check for users wishing to verify their beam model commissioning and ongoing quality assurance efforts.

  • Open Access

    First experience with third‐party validations: A robust calibration and QA procedure for proton FLASH delivery

    by Chih‐Chiang Chang, Balaji Selvaraj, Xingyi Zhao, Jacob Rembish, Paige A. Taylor, Alexander Bookbinder, Chingyun Cheng, J. Isabelle Choi, Charles B. Simone, Haibo Lin, et al.

    Background: Proton FLASH radiotherapy, delivering ultra‐high dose rates, shows promise in reducing normal tissue toxicity while maintaining tumor control. However, accurate dosimetry and quality assurance (QA) for FLASH remain challenging due to the extreme dose rates involved. Developing reliable calibration and QA procedures is crucial for advancing FLASH towards clinical implementation. Purpose: To present an effective routine calibration and QA procedure for proton FLASH delivery to ensure high‐quality dosimetry performance for preclinical and clinical delivery. Methods: A high temporospatial resolution strip ionization chamber array (SICA) detector was mounted to the treatment nozzle, which was calibrated using an Advanced Markus ion chamber (IC) under variable dose and ultra‐high dose rates. The calibration curve was used to monitor the delivery in real‐time. The maximum beam current was 215 nA at the isocenter at the highest energy of the cyclotron (250 MeV). Third‐party IROC (Imaging and Radiation Oncology Core) thermoluminescent dosimeters (TLDs) were requested to verify the accuracy and effectiveness of the calibration and validation procedure. A transmission field with a field size of 3 × 3 cm 2 was designed to deliver 2000 cGy doses with a field‐averaged dose rate varying from 36 to 76.5 Gy/s. Results: The entire calibration process took less than 10 minutes as part of routine daily QA. The calibration curve between the SICA detector and IC demonstrated an R ‐value of almost 1.00. The SICA detector measured each delivery, providing critical data for FLASH analysis, including field size, dose, delivery time, and dose rate. Based on real‐time dose and dose rate monitoring, the planned and delivered doses were within 1% accuracy according to third‐party TLD measurements. Conclusion: As demonstrated by IROC measurements, effective calibration and QA using a SICA detector for proton FLASH delivery can ensure high accuracy in real‐time dose and dose rate monitoring, paving the way for future clinical applications.


  • Open Access

    NRG Oncology Liver Proton SBRT and Hypofractionated Radiation Therapy: Current Treatment Technical Assessment and Practice Patterns

    by Minglei Kang, Paige A. Taylor, Jiajian Shen, Jun Zhou, Jatinder Saini, Theodore S. Hong, Kristin Higgins, Wei Liu, Ying Xiao, Charles B. Simone, et al.

    Background/Objectives: Proton therapy delivers highly conformal doses to the target area without producing an exit dose, minimizing cumulative doses to healthy liver tissue. This study aims to evaluate current practices, challenges, and variations in the implementation of proton stereotactic body radiation therapy (SBRT) and hypofractionated therapy for liver malignancies, with the goal of providing a technical assessment to promote broader adoption and support future clinical trials. Methods and Materials: An extensive survey was conducted by NRG Oncology across North American proton treatment centers to assess the current practices of proton liver SBRT and hypofractionated therapy. The survey focused on key aspects, including patient selection, prescription and normal tissue constraints, simulation and motion management, treatment planning, quality assurance (QA), treatment delivery, and the use of image-guided radiation therapy (IGRT). Results: This survey captures the current practice patterns and status of proton SBRT and hypofractionated therapy in liver cancer treatment. Proton therapy is increasingly preferred for treating inoperable liver malignancies due to its ability to minimize healthy tissue exposure. However, the precision required for proton therapy presents challenges, particularly in managing uncertainties and target motion during high-dose fractions and short treatment courses. Survey findings revealed significant variability in clinical practices across centers, highlighting differences in motion management, dose fractionation schedules, and QA protocols. Conclusion: Proton SBRT and hypofractionated therapy offer significant potential for treating liver malignancies. A comprehensive approach involving precise patient selection, treatment planning, and QA is essential for ensuring safety and effectiveness. This survey provides valuable insights into current practices and challenges, offering a foundation for technical recommendations to optimize the use of proton therapy and guide future clinical trials.


  • Open Access

    OSLD nanoDot characterization for carbon radiotherapy dosimetry

    by Paige A Taylor, Shannon Hartzell, Alfredo Mirandola, Mario Ciocca, Giuseppe Magro, Paola Alvarez, Christine B Peterson, Christopher R Peeler, Eugene J Koay, Rebecca M Howell, et al.

    Objective . This study characterized optically-stimulated luminescent dosimeter (OSLD) nanoDots for use in a therapeutic carbon beam using the Imaging and Radiation Oncology Core (IROC) framework for remote output verification. Approach . The absorbed dose correction factors for OSLD (fading, linearity, beam quality, angularity, and depletion), as defined by AAPM TG 191, were characterized for carbon beams. For the various correction factors, the effect of linear energy transfer (LET) was examined by characterizing in both a low and high LET setting. Main results . Fading was not statistically different between reference photons and carbon, nor between low and high LET beams; thus, the standard IROC-defined exponential function could be used to characterize fading. Dose linearity was characterized with a linear fit; while low and high LET carbon linearity was different, these differences were small and could be rolled into the uncertainty budget if using a single linearity correction. A linear fit between beam quality and dose-averaged LET was determined. The OSLD response at various angles of incidence was not statistically different, thus a correction factor need not be applied. There was a difference in depletion between low and high LET irradiations in a primary carbon beam, but this difference was small over the standard five readings. The largest uncertainty associated with the use of OSLDs in carbon was because of the k Q correction factor, with an uncertainty of 6.0%. The overall uncertainty budget was 6.3% for standard irradiation conditions. Significance . OSLD nanoDot response was characterized in a therapeutic carbon beam. The uncertainty was larger than for traditional photon applications. These findings enable the use of OSLDs for carbon absorbed dose measurements, but with less accuracy than conventional OSLD audit programs.


  • Open Access

    Prioritizing clinical trial quality assurance for photons and protons: A failure modes and effects analysis (FMEA) comparison

    by Paige A. Taylor, Elizabeth Miles, Lone Hoffmann, Sarah M. Kelly, Stephen F. Kry, Ditte Sloth Møller, Hugo Palmans, Kamal Akbarov, Marianne C. Aznar, Enrico Clementel, et al.


  • The Value of On-Site Proton Audits

    by Paige A. Taylor, Jessica Lowenstein, David Followill, Stephen F. Kry